Maximum Dose for Thioridazine
The maximum recommended daily dose of thioridazine is 800 mg per day for adults, divided into 2-4 doses 1.
Dosing Guidelines
Adults with Schizophrenia
- Starting dose: 50-100 mg three times daily
- Maximum dose: 800 mg/day total
- Maintenance range: 200-800 mg/day in divided doses (2-4 times daily)
- Once symptom control is achieved, gradually reduce to find the minimum effective maintenance dose 1
Pediatric Patients (Schizophrenia, unresponsive to other agents)
- Initial dose: 0.5 mg/kg/day in divided doses
- Maximum dose: 3 mg/kg/day
- Increase gradually until optimal effect or maximum dose reached 1
Critical Safety Considerations
Thioridazine should be reserved exclusively for schizophrenic patients who fail to respond adequately to other antipsychotic drugs due to its dose-related QTc prolongation, which is potentially life-threatening 1.
Cardiac Toxicity Profile
The evidence demonstrates significant cardiac risks:
- Thioridazine produces the greatest QTc prolongation among antipsychotics studied (30.1 ms increase at maximum recommended doses) 2
- Historical case reports document fatal cardiac events at doses of 1500-3600 mg/day, with terminal ECG patterns showing heart block alternating with ventricular tachycardia 3
- Severe intoxication with coma and ventricular arrhythmias occurs at doses ≥2000 mg 4
- Cardiac arrhythmias can persist up to 28 hours after drug intake 4
Common Pitfalls to Avoid
Never exceed 800 mg/day - this is an absolute ceiling, not a flexible guideline. The dose-dependent QTc prolongation makes higher doses extremely dangerous.
Drug interactions are critical: Thioridazine is contraindicated with:
- CYP2D6 inhibitors (fluoxetine, paroxetine) - can elevate thioridazine levels 2.4 to 4.5-fold 1
- Fluvoxamine - increases thioridazine levels 3-fold 1
- Propranolol - increases levels 50-400% 1
- Pindolol - produces moderate dose-related increases 1
- Any drugs that prolong QTc interval 1
Genetic considerations: Approximately 7% of the population has reduced CYP2D6 activity, which dramatically increases thioridazine exposure and cardiac risk 1, 5.
Monitoring Requirements
Given the cardiac risks, patients require:
- Baseline ECG before initiation
- Regular ECG monitoring during treatment
- Complete blood count monitoring in first few months (leukopenia/agranulocytosis risk) 1
- Immediate discontinuation if QTc exceeds 500 ms or severe neutropenia develops
Always use the smallest effective dose - the FDA label explicitly emphasizes individualized dosing to minimize cardiac risk while maintaining efficacy 1.